Pharming Group N.V.
P.O. Box 451
273 articles with Pharming Group N.V.
Pharming Group N.V. announced it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome.
Pharming paid Novartis an upfront fee of $20 million for the asset, a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immune-modulating and potentially anti-neoplastic activities.
Delivered 31% increase in revenue, 51% increase in operating profit and 60% increase in net profit year-on-year Delivered 21% increase in revenue, with increases in operating profit and net profit compared to Q1 2019 Increased investment in pipeline to support long-term growth
Pharming Group N.V. announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.
Pharming Group N.V. announces that at its Annual General Meeting of shareholders, all proposals were approved.
Pharming Group N.V. announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website.
Pharming has acquired its shareholding through the conversion of €2.5 million of existing credits and €1.6 million of new cash subscription for a total of €4.1 million in BioConnection shares, plus additional shares acquired from existing investors.
Pharming Group announces publication of its Annual Report 2018 and a provisional commitment to invest in supplier
Annual Report 2018 is available for download on the Pharming website
Pharming announces abstract presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and sponsorship of the AAAAI Foundation Michael M. Frank, MD, FAAAI Lectureship
Pharming Group N.V. announced that an abstract was presented this week at the American Academy of Allergy, Asthma & Immunology Annual Meeting in San Francisco, CA.
Pharming announces abstracts presented at The Western Society of Allergy, Asthma & Immunology (WSAAI) conference this week
Pharming Group N.V. announced today that two abstracts were presented at The Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA on January 22-24, 2019.
Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies
Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).
Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy
Primary Endpoint was met, with rhC1INH treatment reducing neutrophil gelatinase-associated lipocalin (NGAL), a widely recognized marker of acute renal damage
Additional clinical trial data for prophylaxis of HAE requested
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.
Pharming Announces FDA Acceptance for Review of Supplemental BLA for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
The FDA has indicated that the sBLA is sufficiently complete to permit a substantive review and has set an action date of September 21, 2018.
The newly issued shares represent 4.6% of the outstanding share capital immediately prior to the issue.
Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks
The submission includes data from two completed trials of RUCONEST for the prophylaxis of HAE attacks: a randomized, double-blind, placebo-controlled trial and an open-label study.
Pharming Announces Warrant Exercises and Conversions of Its Ordinary Bonds Into Shares Mostly Through Cashless Exercise
Pharming Group N.V. announced that since the release of its update regarding cashless and other warrant exercises and bond conversions on 10 August 2017.